Sarepta Therapeutics (SRPT) Stock Price, Quote, News & History | Benzinga

Sarepta Therapeutics Inc (SRPT) Stock Price, Quote, News & History

SRPTNASDAQ

Trade with Public

Trade with Public

$16.78

N/A

At close: Aug 7, 5:00 PM EST

$16.85

0.0690.41%

After Hours: Aug 7, 6:35 PM EST

Earnings: Q2 2026 Earnings were released on Wed Aug 5th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 4 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$16.86

Close

$16.78

Volume / Avg.

3.06M / 3.46M

Day Range

$16.47 - $17.26

52 Wk Range

14.68 - 25.32

Market Cap

$1.78B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

32.33%

Days to Cover

9.22

Recent Sarepta Therapeutics, Inc. News

Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.

Vandana Singh

Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as Federal Reserve chair, due at 2 p.m. ET.

Piero Cingari

Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.

Piero Cingari

Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 And AMD: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49, the S&P 500 gaining 0.5% to 6,591.90.

Shivdeep Dhaliwal

Crude Oil Moves Lower; Cintas Raises FY2026 Forecast

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw significant gains.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

111.01M

Investing Cash Flow (TTM)

100.85M

Financing Cash Flow (TTM)

-156.76M

Free Cash Flow (TTM)

74.97M

Capital Expenditure (TTM)

-36.04M

Net Change in Cash (TTM)

55.10M

Analyst Trends and Forecast

1

Feb

2

4

Mar

1

Apr

1

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.03B

PE Ratio (TTM)

-

PE Ratio (FWD)

5.75

PEG Ratio (TTM)

-

PS Ratio (TTM)

0.96

PB Ratio (TTM)

1.16

Earnings Yield % (TTM)

-9.36%

Earnings Yield % (FWD)

17.40%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

25.16

Book Value / Share

$14.46

Company Debt

Total Debt

$847.62M

LT Debt

$847.62M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$584.07M

Total Cash

$571.15M

Debt to Equity

0.68

Issuance of Debt (TTM)

-$159.07M

Repayment of Debt (TTM)

-$584.07M

Key Statistics

Open

$16.86

Close

$16.78

Volume / Avg.

3.06M / 3.46M

Day Range

$16.47 - $17.26

52 Wk Range

14.68 - 25.32

Market Cap

$1.78B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

32.33%

Days to Cover

9.22

About

Sector

Health Care

Industry

Biotechnology

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The comp...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Sarepta Therapeutics (SRPT) stock?

A

You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Sarepta Therapeutics (SRPT) competitors?

A

Other companies in Sarepta Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

A

Sarepta Therapeutics has a consensus price target of $24.89.

Q

What is the current price for Sarepta Therapeutics (SRPT)?

A

The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $16.849 last updated August 7, 2026 at 6:35 PM EDT.

Q

Does Sarepta Therapeutics (SRPT) pay a dividend?

A

There are no upcoming dividends for Sarepta Therapeutics.

Q

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

A

Sarepta Therapeutics does not have any upcoming earnings scheduled.

Q

Is Sarepta Therapeutics (SRPT) going to split?

A

There is no upcoming split for Sarepta Therapeutics.

Q

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

A

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.